Yiqing Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yiqing Zhao has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Hongfang Liu
Department of Quantitative and Systems Health Sciences, University of Texas at Austin Dell Medical School, Austin, TX 78712, USA
25 shared publications - Chen Wang
Mayo Clinic
24 shared publications - Anastasios Dimou
Department of Oncology, Mayo Clinic, Rochester, MN
18 shared publications - Jun Jiang
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota
17 shared publications - William Bruce Wong
Genentech, Inc., South San Francisco, CA
17 shared publications - Zachary C. Fogarty
Division of Computational Biology, Mayo Clinic Rochester , 200 First St SW , Rochester, MN 55905
17 shared publications
Latest Publications
- Open Access
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Data from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Advances in genetic technology have led to the increasing use of genomic panels in precision oncology practice, with panels ranging from a couple to hundreds of genes. However, the clinical utilization and utility of oncology genomic panels, especially among vulnerable populations, is unclear. We examined the association of panel size with socioeconomic status and clinical trial matching. We retrospectively identified 9,886 eligible adult subjects in the Mayo Clinic Health System who underwent genomic testing between January 1, 2016 and June 30, 2020. Patient data were retrieved from structured and unstructured data sources of institutional collections, including cancer registries, clinical data warehouses, and clinical notes. Socioeconomic surrogates were approximated using the Area Deprivation Index (ADI) corresponding to primary residence addresses. Logistic regression was performed to analyze relationships between ADI or rural/urban status and (i) use of genomic test by panel size; (ii) clinical trial matching status. Compared with patients from the most affluent areas, patients had a lower odds of receiving a panel test (vs. a single-gene test) if from areas of higher socioeconomic deprivation [OR (95% confidence interval (CI): 0.71 (0.61–0.83), P < 0.01] or a rural area [OR (95% CI): 0.85 (0.76–0.96), P < 0.01]. Patients in areas of higher socioeconomic deprivation were less likely to be matched to clinical trials if receiving medium panel tests [(OR) (95% CI): 0.69 (0.49–0.97), P = 0.03]; however, there was no difference among patients receiving large panel tests (P > 0.05) and rural patients were almost 2x greater odds of being matched if receiving a large panel test [(OR) (95% CI): 1.76 (1.21–2.55), P < 0.01].Significance:We identified socioeconomic and rurality disparities in the use of genomic tests and trial matching by panel size, which may have implications for equal access to targeted therapies. The lack of association between large panel tests and clinical trial matching by socioeconomic status, suggests a potential health equity impact, while removing barriers in access to large panels for rural patients may improve access to trials. However, further research is needed.
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Advances in genetic technology have led to the increasing use of genomic panels in precision oncology practice, with panels ranging from a couple to hundreds of genes. However, the clinical utilization and utility of oncology genomic panels, especially among vulnerable populations, is unclear. We examined the association of panel size with socioeconomic status and clinical trial matching. We retrospectively identified 9,886 eligible adult subjects in the Mayo Clinic Health System who underwent genomic testing between January 1, 2016 and June 30, 2020. Patient data were retrieved from structured and unstructured data sources of institutional collections, including cancer registries, clinical data warehouses, and clinical notes. Socioeconomic surrogates were approximated using the Area Deprivation Index (ADI) corresponding to primary residence addresses. Logistic regression was performed to analyze relationships between ADI or rural/urban status and (i) use of genomic test by panel size; (ii) clinical trial matching status. Compared with patients from the most affluent areas, patients had a lower odds of receiving a panel test (vs. a single-gene test) if from areas of higher socioeconomic deprivation [OR (95% confidence interval (CI): 0.71 (0.61–0.83), P < 0.01] or a rural area [OR (95% CI): 0.85 (0.76–0.96), P < 0.01]. Patients in areas of higher socioeconomic deprivation were less likely to be matched to clinical trials if receiving medium panel tests [(OR) (95% CI): 0.69 (0.49–0.97), P = 0.03]; however, there was no difference among patients receiving large panel tests (P > 0.05) and rural patients were almost 2x greater odds of being matched if receiving a large panel test [(OR) (95% CI): 1.76 (1.21–2.55), P < 0.01].Significance:We identified socioeconomic and rurality disparities in the use of genomic tests and trial matching by panel size, which may have implications for equal access to targeted therapies. The lack of association between large panel tests and clinical trial matching by socioeconomic status, suggests a potential health equity impact, while removing barriers in access to large panels for rural patients may improve access to trials. However, further research is needed.
- Open Access
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
TABLE 2 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Time to test return (turnaround time) for large panel, medium panel, and single-gene genomic tests
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 2 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Time to test return (turnaround time) for large panel, medium panel, and single-gene genomic tests
- Open Access
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Trends of single-gene, medium, large genomic test panel distribution among patients with lung cancer and non-lung cancer. A, Proportion and total number of genetic tests over time by size [large panel (50+ genes), medium panel (2 to 49 genes), single-gene] among patients with a lung cancer diagnosis. B, Proportion and total number of genetic tests over time by size [large panel (50+ genes), medium panel (2 to 49 genes), single-gene] among patients with a non-lung cancer diagnosis.
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Trends of single-gene, medium, large genomic test panel distribution among patients with lung cancer and non-lung cancer. A, Proportion and total number of genetic tests over time by size [large panel (50+ genes), medium panel (2 to 49 genes), single-gene] among patients with a lung cancer diagnosis. B, Proportion and total number of genetic tests over time by size [large panel (50+ genes), medium panel (2 to 49 genes), single-gene] among patients with a non-lung cancer diagnosis.
- Open Access
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
TABLE 3 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Association of panel size with ADI and urban/rural statusa
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 3 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Association of panel size with ADI and urban/rural statusa
- Open Access
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
TABLE 1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Demographic characteristics of patients
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Demographic characteristics of patients
- Open Access
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Supplemental Table S1 shows the association of area level deprivation and rurality with genomic test type in the subgroup of patients with known stage of disease
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Supplemental Table S1 shows the association of area level deprivation and rurality with genomic test type in the subgroup of patients with known stage of disease
- Open Access
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
TABLE 1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Demographic characteristics of patients
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Demographic characteristics of patients
- Open Access
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Data from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Advances in genetic technology have led to the increasing use of genomic panels in precision oncology practice, with panels ranging from a couple to hundreds of genes. However, the clinical utilization and utility of oncology genomic panels, especially among vulnerable populations, is unclear. We examined the association of panel size with socioeconomic status and clinical trial matching. We retrospectively identified 9,886 eligible adult subjects in the Mayo Clinic Health System who underwent genomic testing between January 1, 2016 and June 30, 2020. Patient data were retrieved from structured and unstructured data sources of institutional collections, including cancer registries, clinical data warehouses, and clinical notes. Socioeconomic surrogates were approximated using the Area Deprivation Index (ADI) corresponding to primary residence addresses. Logistic regression was performed to analyze relationships between ADI or rural/urban status and (i) use of genomic test by panel size; (ii) clinical trial matching status. Compared with patients from the most affluent areas, patients had a lower odds of receiving a panel test (vs. a single-gene test) if from areas of higher socioeconomic deprivation [OR (95% confidence interval (CI): 0.71 (0.61–0.83), P < 0.01] or a rural area [OR (95% CI): 0.85 (0.76–0.96), P < 0.01]. Patients in areas of higher socioeconomic deprivation were less likely to be matched to clinical trials if receiving medium panel tests [(OR) (95% CI): 0.69 (0.49–0.97), P = 0.03]; however, there was no difference among patients receiving large panel tests (P > 0.05) and rural patients were almost 2x greater odds of being matched if receiving a large panel test [(OR) (95% CI): 1.76 (1.21–2.55), P < 0.01].Significance:We identified socioeconomic and rurality disparities in the use of genomic tests and trial matching by panel size, which may have implications for equal access to targeted therapies. The lack of association between large panel tests and clinical trial matching by socioeconomic status, suggests a potential health equity impact, while removing barriers in access to large panels for rural patients may improve access to trials. However, further research is needed.
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Advances in genetic technology have led to the increasing use of genomic panels in precision oncology practice, with panels ranging from a couple to hundreds of genes. However, the clinical utilization and utility of oncology genomic panels, especially among vulnerable populations, is unclear. We examined the association of panel size with socioeconomic status and clinical trial matching. We retrospectively identified 9,886 eligible adult subjects in the Mayo Clinic Health System who underwent genomic testing between January 1, 2016 and June 30, 2020. Patient data were retrieved from structured and unstructured data sources of institutional collections, including cancer registries, clinical data warehouses, and clinical notes. Socioeconomic surrogates were approximated using the Area Deprivation Index (ADI) corresponding to primary residence addresses. Logistic regression was performed to analyze relationships between ADI or rural/urban status and (i) use of genomic test by panel size; (ii) clinical trial matching status. Compared with patients from the most affluent areas, patients had a lower odds of receiving a panel test (vs. a single-gene test) if from areas of higher socioeconomic deprivation [OR (95% confidence interval (CI): 0.71 (0.61–0.83), P < 0.01] or a rural area [OR (95% CI): 0.85 (0.76–0.96), P < 0.01]. Patients in areas of higher socioeconomic deprivation were less likely to be matched to clinical trials if receiving medium panel tests [(OR) (95% CI): 0.69 (0.49–0.97), P = 0.03]; however, there was no difference among patients receiving large panel tests (P > 0.05) and rural patients were almost 2x greater odds of being matched if receiving a large panel test [(OR) (95% CI): 1.76 (1.21–2.55), P < 0.01].Significance:We identified socioeconomic and rurality disparities in the use of genomic tests and trial matching by panel size, which may have implications for equal access to targeted therapies. The lack of association between large panel tests and clinical trial matching by socioeconomic status, suggests a potential health equity impact, while removing barriers in access to large panels for rural patients may improve access to trials. However, further research is needed.
- Open Access
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
TABLE 2 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Time to test return (turnaround time) for large panel, medium panel, and single-gene genomic tests
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 2 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Time to test return (turnaround time) for large panel, medium panel, and single-gene genomic tests
- Open Access
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Supplementary Table S2 shows the association of area level deprivation and rurality with clinical trial matching among patients with known stage of disease
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Supplementary Table S2 shows the association of area level deprivation and rurality with clinical trial matching among patients with known stage of disease